Alexion Snags 2nd FDA Voucher On Kanuma Win
This article was originally published in Scrip
The FDA's approval on Dec. 8 of Alexion Pharmaceuticals Inc.'s enzyme replacement therapy (ERT) Kanuma (sebelipase alfa) was significant for several reasons – mostly, because it provides patients with the first treatment in the US for a deadly, progressive ultra-rare genetic disease, known as lysosomal acid lipase deficiency (LAL-D), which causes multi-organ damage, resulting in premature death.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.